Source comparison
Best PT-141 Dosage for HSDD: Dosing Options Comparison
0.75mg Phase 2 trial data only Minimal receptor activation. FSFI desire score increases statistically indistinguishable from placebo Nausea in <15%. Well-tolerated but ineffective Not therapeutically viable. Receptor occupancy too low for measurable CNS effect
This comparison does not assign a generated winner or score.
- 0.75mg
- Phase 2 trial data only
- Minimal receptor activation. FSFI desire score increases statistically indistinguishable from placebo
- Nausea in <15%. Well-tolerated but ineffective
- Not therapeutically viable. Receptor occupancy too low for measurable CNS effects
- 1.25mg
- Subtherapeutic. 0.18-point FSFI increase vs placebo (not significant)
- Nausea in 25%. Side effect burden without corresponding benefit
- Failed to meet efficacy endpoints. Abandoned in Phase 3 development
- 1.75mg
- FDA-approved based on RECONNECT trials
- 0.31-point FSFI increase (p<0.05). 25% responder rate defined as ≥2-point improvement
- Nausea in 40%, flushing in 20%, discontinuation rate 18%
- Optimal therapeutic dose. Only dose demonstrating statistically significant and clinically meaningful efficacy
- 2.0mg+
- Not studied in Phase 3
- Theoretical receptor saturation but no efficacy data beyond 1.75mg
- Nausea approaches 60%. Dose-limiting emetic effects
- No evidence of superior efficacy. Higher side effect burden makes this dose unjustifiable